Retinal Vein Occlusion - Pipeline Insight, 2022

DelveInsight’s, “Retinal Vein Occlusion – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Retinal Vein Occlusion Understanding
Retinal Vein Occlusion: Overview
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old. Systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia have all been implicated as other primary risk factors for central retinal vein occlusion. Other associated risk factors include smoking, optic disc drusen, optic disc edema, hypercoagulable state (polycythemia, multiple myeloma, cryoglobulinemia, Waldenstrom macroglobulinemia, antiphospholipid syndrome, Leiden factor V, activated protein C resistance, hyperhomocysteinemia, Protein C and S deficiency, antithrombin III mutation, prothrombin mutation), syphilis, sarcoidosis, African American race, sickle cell, HIV, vasculitis, drugs such as oral contraceptives or diuretics, abnormal platelet function, orbital disease, and rarely migraines.
No totally effective medical treatment is available for either the prevention or treatment of central retinal vein occlusion. Surgical interventions include laser photocoagulation, chorioretinal venous anastomosis, radial optic neurotomy, and vitrectomy. There are specific surgical and laser approaches have been found to potentially improve visual acuity in patients with central retinal vein occlusion. Pars plana vitrectomy (PPV) can be done when central retinal vein occlusions have an associated vitreous hemorrhage. PPV may be used to clear the hemorrhage from the visual axis and allows for better visualization of the retina. A PPV may also ablate neovascularization that can cause neovascular glaucoma in the anterior segment. Laser pan-retinal photocoagulation (PRP) can be done to treat neovascularization, with the goal of devitalizing some of the retinal tissue to prevent further neovascularization and treat iris neovascularization. There is no evidence at this time supporting prophylactic PRP without neovascularization.

Retinal Vein Occlusion Emerging Drugs Chapters
This segment of the Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinal Vein Occlusion Emerging Drugs
KSI-301: Kodiak sciences
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.
601: Sunshine Guojian Pharmaceutical
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.
IBE-814: Ripple Therapeutics
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).
Further product details are provided in the report……..

Retinal Vein Occlusion: Therapeutic Assessment
This segment of the report provides insights about the different Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Retinal Vein Occlusion
There are approx. 15+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak sciences
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III )
Mid-Stage products (Phase II)
Early-stage products ( Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Peptide
Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinal Vein Occlusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinal Vein Occlusion drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve Retinal Vein Occlusion.
Retinal Vein Occlusion Report Insights
Retinal Vein Occlusion Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Retinal Vein Occlusion Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Retinal Vein Occlusion drugs?
How many Retinal Vein Occlusion drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinal Vein Occlusion?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinal Vein Occlusion therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Retinal Vein Occlusion and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Kodiak Sciences
Hoffman-La-Roche
iRenix Medical, Inc.
Sunshine Guojian Pharmaceutical
Ripple Therapeutics
Aerpio Therapeutics
The Emmes Company
Novartis
Shanghai BDgene
AsclepiX Therapeutics
Taiwan Liposome Company
Clearside Biomedical
Gene Signal
Ocular Therapeutix
Ocuphire Pharma
Eyevensys

Key Products
KSI-301
Faricimab
IRX-101
601
IBE-814
AKB-9778
Autologous Bone Marrow CD34+ Stem Cells
MHU650
BD311
TLC399
CLS-TA
APX 3330
EYS809
Aganirsen
Brolucizumab

Companies

Kodiak Sciences
Hoffman-La-Roche
iRenix Medical, Inc.
Sunshine Guojian Pharmaceutical
Ripple Therapeutics
Aerpio Therapeutics
The Emmes Company
Novartis
Shanghai BDgene
AsclepiX Therapeutics
Taiwan Liposome Company
Clearside Biomedical
Gene Signal
Ocular Therapeutix
Ocuphire Pharma
Eyevensys


Introduction
Executive Summary
Retinal Vein Occlusion: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
KSI-301: Kodiak sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
601: Sunshine Guojian Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
MHU650: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Retinal Vein Occlusion Key Companies
Retinal Vein Occlusion Key Products
Retinal Vein Occlusion- Unmet Needs
Retinal Vein Occlusion- Market Drivers and Barriers
Retinal Vein Occlusion- Future Perspectives and Conclusion
Retinal Vein Occlusion Analyst Views
Retinal Vein Occlusion Key Companies
Appendix
Table 1 Total Products for Retinal Vein Occlusion
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Retinal Vein Occlusion
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings